Top

Published in:

01-01-2017 | Original Communication

Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy

Authors: R. J. Willcocks, W. T. Triplett, S. C. Forbes, H. Arora, C. R. Senesac, D. J. Lott, T. R. Nicholson, W. D. Rooney, G. A. Walter, K. Vandenborne

Published in: Journal of Neurology | Issue 1/2017

Abstract

There is a pressing need for biomarkers and outcomes that can be used across disease stages in Duchenne muscular dystrophy (DMD), to facilitate the inclusion of a wider range of participants in clinical trials and to improve our understanding of the natural history of DMD. Quantitative magnetic resonance imaging (qMRI) and spectroscopy (MRS) biomarkers show considerable promise in both the legs and forearms of individuals with DMD, but have not yet been examined in functionally important proximal upper extremity muscles such as the biceps brachii and deltoid. The primary objective of this study was to examine the feasibility of implementing qMRI and MRS biomarkers in the proximal upper extremity musculature, and the secondary objective was to examine the relationship between MR measures of arm muscle pathology and upper extremity functional endpoints. Biomarkers included MRS and MRI measures of fat fraction and transverse relaxation time (T ₂). The MR exam was well tolerated in both ambulatory and non-ambulatory boys. qMR biomarkers differentiated affected and unaffected participants and correlated strongly with upper extremity function (r = 0.91 for biceps brachii T ₂ versus performance of upper limb score). These qMR outcome measures could be highly beneficial to the neuromuscular disease community, allowing measurement of the quality of functionally important muscles across disease stages to understand the natural history of DMD and particularly to broaden the opportunity for clinical trial participation.

Akima H, Lott D, Senesac C, Deol J, Germain S, Arpan I, Bendixen R, Lee Sweeney H, Walter G, Vandenborne K (2012) Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. Neuromuscul Disord 22:16–25CrossRefPubMed

Arpan I, Forbes SC, Lott DJ, Senesac CR, Daniels MJ, Triplett WT, Deol JK, Sweeney HL, Walter GA, Vandenborne K (2013) T ₂ mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5–15-year-old boys with Duchenne muscular dystrophy. NMR Biomed 26:320–328CrossRefPubMed

Arpan I, Willcocks RJ, Forbes SC, Finkel RS, Lott DJ, Rooney WD, Triplett WT, Senesac CR, Daniels MJ, Byrne BJ, Finanger EL, Russman BS, Wang DJ, Tennekoon GI, Walter GA, Sweeney HL, Vandenborne K (2014) Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology 83:974–980CrossRefPubMedPubMedCentral

Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, King WM, Pandya S, Robison J, Schierbecker J (1989) Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 39:475–481CrossRefPubMed

Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ (1981) Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 4:186–197CrossRefPubMed

Elliott MA, Walter GA, Swift A, Vandenborne K, Schotland JC, Leigh JS (1999) Spectral quantitation by principal component analysis using complex singular value decomposition. Magn Reson Med 41:450–455CrossRefPubMed

Fischmann A, Hafner P, Gloor M, Schmid M, Klein A, Pohlman U, Waltz T, Gonzalez R, Haas T, Bieri O, Fischer D (2013) Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol 260:969–974CrossRefPubMed

Forbes SC, Willcocks RJ, Triplett WT, Rooney WD, Lott DJ, Wang DJ, Pollaro J, Senesac CR, Daniels MJ, Finkel RS, Russman BS, Byrne BJ, Finanger EL, Tennekoon GI, Walter GA, Sweeney HL, Vandenborne K (2014) Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with duchenne muscular dystrophy: a multicenter cross sectional study. PLoS One 9:e106435CrossRefPubMedPubMedCentral

Gambarota G, Cairns BE, Berde CB, Mulkern RV (2001) Osmotic effects on the T₂ relaxation decay of in vivo muscle. Magn Reson Med 46:592–599CrossRefPubMed

10.

Hogrel JY, Wary C, Moraux A, Azzabou N, Decostre V, Ollivier G, Canal A, Lilien C, Ledoux I, Annoussamy M, Reguiba N, Gidaro T, Le Moing AG, Cardas R, Voit T, Carlier PG, Servais L (2016) Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology 86:1022–1030CrossRefPubMedPubMedCentral

11.

Kim HK, Laor T, Horn PS, Wong B (2010) Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol 11:304–311CrossRefPubMedPubMedCentral

12.

Lynn S, Aartsma-Rus A, Bushby K, Furlong P, Goemans N, De Luca A, Mayhew A, McDonald C, Mercuri E, Muntoni F, Pohlschmidt M, Verschuuren J, Voit T, Vroom E, Wells DJ, Straub V (2015) Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscul Disord 25:96–105CrossRefPubMed

13.

Mattar FL, Sobreira C (2008) Hand weakness in Duchenne muscular dystrophy and its relation to physical disability. Neuromuscul Disord 18:193–198CrossRefPubMed

14.

Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, Vandenhauwe M, Klingels K, Florence J, Main M, Bianco F, Henrikson E, Servais L, Campion G, Vroom E, Ricotti V, Goemans N, McDonald C, Mercuri E, Group PotULW (2013) Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55:1038–1045CrossRefPubMed

15.

Nelder JA, Mead R (1965) A simplex method for function minimization. Comput J 7:308–313CrossRef

16.

Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, Sivo S, D’Amico A, Messina S, Battini R, Scutifero M, Petillo R, Frosini S, Scalise R, Vita G, Bruno C, Pedemonte M, Mongini T, Pegoraro E, Brustia F, Gardani A, Berardinelli A, Lanzillotta V, Viggiano E, Cavallaro F, Sframeli M, Bello L, Barp A, Bonfiglio S, Rolle E, Colia G, Catteruccia M, Palermo C, D’Angelo G, Pini A, Iotti E, Gorni K, Baranello G, Morandi L, Bertini E, Politano L, Sormani M, Mercuri E (2014) Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 24:201–206CrossRefPubMed

17.

Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, Rosaria Cecio M, Torre V, DE Luca F, Picillo E, Paciello O, Piluso G, Nigro G, Politano L (2012) Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol 31:121–125PubMedPubMedCentral

18.

Ricotti V, Evans MR, Sinclair C, Morrow JM, Janiczek RL, Hanna MG, Yousry T, Muntoni F, Thornton J (2014) Upper limb muscle fat-water quantification in non-ambulant Duchenne muscular dystrophy. In: International Society for Magnetic Resonance in Medicine, Milan

19.

Triplett WT, Baligand C, Forbes SC, Willcocks RJ, Lott DJ, DeVos S, Pollaro J, Rooney WD, Sweeney HL, Bönnemann CG, Wang DJ, Vandenborne K, Walter GA (2014) Chemical shift-based MRI to measure fat fractions in dystrophic skeletal muscle. Magn Reson Med 72:8–19CrossRefPubMed

20.

Wary C, Azzabou N, Giraudeau C, Le Louër J, Montus M, Voit T, Servais L, Carlier P (2015) Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy. NMR Biomed 28:1150–1162CrossRefPubMed

21.

Willcocks RJ, Arpan IA, Forbes SC, Lott DJ, Senesac CR, Senesac E, Deol J, Triplett WT, Baligand C, Daniels MJ, Sweeney HL, Walter GA, Vandenborne K (2014) Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 24:393–401CrossRefPubMedPubMedCentral

22.

Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, Daniels MJ, Wang DJ, Harrington AT, Tennekoon GI, Russman BS, Finanger EL, Byrne BJ, Finkel RS, Walter GA, Sweeney HL, Vandenborne K (2016) Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann Neurol 79:535–547CrossRefPubMed

23.

Wokke BH, Bos C, Reijnierse M, van Rijswijk CS, Eggers H, Webb A, Verschuuren JJ, Kan HE (2013) Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients. J Magn Reson Imaging 38:619–624CrossRefPubMed

24.

Wren TA, Bluml S, Tseng-Ong L, Gilsanz V (2008) Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol 190:W8–12CrossRefPubMed

Title: Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy
Authors: R. J. Willcocks
W. T. Triplett
S. C. Forbes
H. Arora
C. R. Senesac
D. J. Lott
T. R. Nicholson
W. D. Rooney
G. A. Walter
K. Vandenborne
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 1/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-016-8311-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

New evidence for involvement of ESR1 gene in susceptibility to Chinese migraine

Frenchay dysarthria assessment (FDA-2) in Parkinson’s disease: cross-cultural adaptation and psychometric properties of the European Portuguese version

Exercise effects in Huntington disease

Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies

ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia

Pathological laughter as onset symptom in atypical parkinsonisms